Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study

Key facts

Sponsor

Sanguine Biosciences

Principal Investigator

Andrew C Frisina, M.S.

Intervention

Biospecimen Collection(other)

Enrollment

5 enrolled

Eligibility

25-65 years · All sexes

Timeline

2023 – 2025

Study locations (1)

• Sanguine Biosciences, Inc., Woburn, Massachusetts, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Huntington disease

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07513844
  Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's Disease
  First Affiliated Hospital of Fujian Medical University
• ENROLLING BY INVITATIONPHASE2, PHASE3NCT07537075
  An Extension of SKY-0515 in Participants With Huntington's Disease
  Skyhawk Therapeutics, Inc.
• RECRUITINGPHASE3NCT07326709
  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
  Novartis Pharmaceuticals
• RECRUITINGPHASE1, PHASE2NCT07451613
  Safety and Tolerability Study of Human Neural Stem Cells for Huntington's Disease
  Leslie Thompson
• RECRUITINGEARLY PHASE1NCT06634628
  iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009
  CHDI Foundation, Inc.
• RECRUITINGPHASE2, PHASE3NCT07378644
  Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease
  Skyhawk Therapeutics, Inc.
• RECRUITINGNCT07253038
  Evaluation of Three Tests to Assess Social Cognition in Huntington Disease
  Region Skane
• RECRUITINGNANCT07213648
  Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
  University of Virginia

See all trials for Huntington disease →